Statements (16)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Amgen
|
| gptkbp:acquisitionYear |
2021
|
| gptkbp:focus |
immuno-oncology
protein therapeutics |
| gptkbp:foundedYear |
2001
|
| gptkbp:founder |
gptkb:Lewis_T._Williams
|
| gptkbp:headquartersLocation |
gptkb:South_San_Francisco,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Five Prime Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:bemarituzumab
|
| gptkbp:stockSymbol |
gptkb:FPRX
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:website |
https://www.fiveprime.com/
|
| gptkbp:bfsParent |
gptkb:Brook_Byers
|
| gptkbp:bfsLayer |
6
|